The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study.

[1]  A. Bazarbachi,et al.  Trends in hematopoietic stem cell transplant activity in Lebanon. , 2017, Hematology/oncology and stem cell therapy.

[2]  L. Milani,et al.  Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments , 2017, The AAPS Journal.

[3]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy , 2017, Clinical pharmacology and therapeutics.

[4]  Julia M. Barbarino,et al.  PharmGKB summary: voriconazole pathway, pharmacokinetics , 2017, Pharmacogenetics and genomics.

[5]  A. Ghavamzadeh,et al.  Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients , 2017, Journal of research in pharmacy practice.

[6]  A. Bazarbachi,et al.  Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions. , 2016, Clinical lymphoma, myeloma & leukemia.

[7]  J. McCune,et al.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II , 2016, Clinical Pharmacokinetics.

[8]  K. Thursky,et al.  Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. , 2015, The Journal of antimicrobial chemotherapy.

[9]  J. Oh,et al.  Population Pharmacokinetics of Cyclosporine in Hematopoietic Stem Cell Transplant Patients , 2015, The Annals of pharmacotherapy.

[10]  J. McCune,et al.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I , 2015, Clinical Pharmacokinetics.

[11]  J. Szer,et al.  Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014 , 2014, Internal medicine journal.

[12]  L. Pagano,et al.  Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  Yan Li,et al.  A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese. , 2013, American journal of hypertension.

[14]  L. Weimin,et al.  Elevation of blood ciclosporin levels by voriconazole leading to leukoencephalopathy , 2013, Journal of pharmacology & pharmacotherapeutics.

[15]  Julia M. Barbarino,et al.  PharmGKB summary: cyclosporine and tacrolimus pathways , 2013, Pharmacogenetics and genomics.

[16]  Walid Rasheed,et al.  Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey. , 2013, Hematology/oncology and stem cell therapy.

[17]  Jae-Gook Shin,et al.  Pharmacokinetic effect of voriconazole on cyclosporine in the treatment of aspergillosis after renal transplantation. , 2012, Clinical nephrology.

[18]  Jun Kato,et al.  Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation , 2012, Clinical transplantation.

[19]  G. Gervasini,et al.  ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients , 2012, European Journal of Clinical Pharmacology.

[20]  S. Park,et al.  Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  H. Inoko,et al.  Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients , 2011, Bone Marrow Transplantation.

[22]  J. Li-Ling,et al.  Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients , 2011, Pharmacological reports : PR.

[23]  K. Sepkowitz,et al.  IDSA GUIDELINES Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America , 2022 .

[24]  C. Craddock,et al.  Prediction of Intravenous Cyclosporine Area Under the Concentration–Time Curve After Allogeneic Stem Cell Transplantation , 2010, Therapeutic drug monitoring.

[25]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II , 2010, Clinical pharmacokinetics.

[26]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.

[27]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  Jun Kato,et al.  Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients , 2009, Bone Marrow Transplantation.

[29]  K. Guthrie,et al.  Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation , 2008, The Pharmacogenomics Journal.

[30]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. Beckmann,et al.  Association of ABCB1 genetic variants with renal function in Africans and in Caucasians , 2008, BMC Medical Genomics.

[32]  J. Kolesar,et al.  Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[33]  P. Carver,et al.  Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants , 2006, Pharmacotherapy.

[34]  W. Weimar,et al.  Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR‐1, CYP3A4, and CYP3A5 genes , 2004, Clinical pharmacology and therapeutics.

[35]  D. Tregouet,et al.  CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation , 2004, Clinical pharmacology and therapeutics.

[36]  M. Fromm,et al.  Clinical aspects of the MDR1 (ABCB1) gene polymorphism. , 2004, Therapeutic drug monitoring.

[37]  J. Squifflet,et al.  The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. , 2004, Pharmacogenetics.

[38]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[39]  B. Meibohm,et al.  The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients , 2003, Journal of clinical pharmacology.

[40]  N. Wood,et al.  Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients , 2002, Clinical pharmacology and therapeutics.

[41]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[42]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.